Company intelligence / Profile preview

AccuRef Diagnostics

California, United States

Ownership: Private
Development stage: Other

Overview

AccuRef Diagnostics develops and commercializes CRISPR-engineered cell-line-based cancer reference materials for clinical genomics applications including qPCR, dPCR, Sanger, mass spec, and small targeted NGS panels. Exclusive partnership with SeraCare announced in 2018 for global distribution starting 2019 (except China).

Industry: Molecular Diagnostics

Partnerships

SeraCare Life Sciences (exclusive partnership)

Beyond the preview

Go deeper on AccuRef Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccuRef Diagnostics.

Explore the full profile